Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
Iridex announced publication of a two-year retrospective study showing sustained IOP reduction with MicroPulse TLT across early, moderate, and advanced primary glaucoma. In 84 eyes of 53 patients, mean IOP fell from 22.32 to 14.05 mmHg and topical medication burden dropped from 2.96 to 2.38, with success rates of 86% in POAG and 81% in PACG eyes and no complications reported.
Key figures
- Follow up
- 24 months
- Study size
- 84 eyes of 53 patients
- Baseline iop mm Hg
- 22.32
- Success rate pacg
- 81%
- Success rate poag
- 86%
- Medications baseline
- 2.96
- Iop at 24 months mm Hg
- 14.05
- Medications at 24 months
- 2.38
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.